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when compared to an equivalent dose of glucosamine hydrochlo-
ride. Whether this difference in synovial levels of glucosamine
attained is translated into a therapeutic effect on the joint tissues
remains to be elucidated.
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Purpose: Evaluation of disease modifying osteoarthritis drug
(DMOADs) in hip osteoarthritis (OA) is based on effects on both
symptoms and structure. Such a beneﬁcial effect might result
in a subsequent hard end-point (e.g. requirement to total hip
replacement (THR).
The objective of this study was to evaluate the long term (5 years)
effect on requirement for THR of a 3 years intake of diacerein in
comparison to placebo in hip OA.
Methods: Two periods: a) 3 years controlled trial evaluating
the effects on the structure and the symptoms of 50 mg diac-
erein b.i.d. versus placebo (Dougados M, et al. Evaluation of
the structure modifying effects of diacerein in hip osteoarthri-
tis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis
Rheum 2001;44:2539-47); b) 5 years follow-up via an annual
phone call contact. Collected data: at baseline demographics
and OA characteristics (femoral head migration, radiological joint
space width [JSW]). During the 3 years of the therapeutical trial
and the 5 years of follow-up: requirement to THR. Analysis: pri-
mary analysis: percentage of patients requiring THR with regard
to the treatment group in patients completing the 3 years placebo
controlled trial (clinical trial completers) using life table analysis
technique and log-rank test; secondary analyses: identical end-
points and statistical analysis but a) in the whole population
entering the trial at year 0, b) in the sub-group of patients with
supero-lateral and concentric femoral head migration (excluding
the patients with a supero-medial femoral head migration) and a
baseline (year 0) JSW of at least 1.5 mm as suggested by the
Barcelona consensus meeting (Altman RD, et al. Measurement
of structural progression in osteoarthritis of the hip: the Barcelona
consensus group. Osteoarthritis Cartilage 2004;12:515-24.).
Results: Of the 507 included patients (255 and 252 in the
diacerein and placebo groups, respectively), 262 completed the
3 years of the therapeutical trial (127 in the diacerein group).
For these patients, a THR was required during the subsequent
5 years in 40% after diacerein intake versus 43% after placebo
(p=0.60). In the whole group of patients entering the trial, a THR
was performed at the end of the 8 years follow-up period in 56%
whatever the initial treatment group (p=0.94). In the sub-group
of 283 patients fulﬁlling the criteria proposed by the Barcelona
consensus group at entry (149 in the diacerein group), a THR
was performed at the end of the 8 years follow-up period in 49%
after diacerein intake vs 55% after placebo, (p=0.50). In this sub-
group, 157 patients (81 in the diacerein group) completed the 3
years of the therapeutical trial. For these patients, a THR was
required during the subsequent 5 years in 32% after diacerein
intake vs 44% after placebo (p=0.21).
Conclusions: This study failed to demonstrate a statistical sig-
niﬁcant difference between the two treatment groups with regard
to the requirement to THR after a 3 years intake of diacerein in
the a priori deﬁned primary analysis. However, the trend in favor
of diacerein in different clinically relevant sub-populations sug-
gests that a 3 years intake of diacerein might have a subsequent
long term beneﬁcial effect in a sub-group of hip OA patients.
Such ﬁndings should be evaluated in further clinical trials.
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Purpose: Crystalline glucosamine sulfate and glucosamine hy-
drochloride alone or in combination with chondroitin sulfate have
been evaluated as a treatment for knee pain from osteoarthri-
tis (OA) in two recent studies of 6-month duration. The NIH-
sponsored GAIT study did not show any effect of treatment
with 500 mg glucosamine hydrochloride three times daily (t.i.d.)
alone or in combination with 400 mg of chondroitin sulfate t.i.d.
Conversely, the GUIDE trial indicated that, at the dose of 1500
mg once-a-day, crystalline glucosamine sulfate soluble powder
provided a signiﬁcant symptomatic effect, thus conﬁrming pre-
vious long-term study observations. The pharmacokinetics of
crystalline glucosamine sulfate 1500 mg once-a-day were re-
cently investigated and showed glucosamine peak plasma levels
in the 10 µM range. These levels were effective in vitro in in-
hibiting IL-1-induced gene expression, currently regarded as the
putative mechanism of action of glucosamine in OA. Conversely,
preliminary studies of the pharmacokinetics of glucosamine after
administration of the glucosamine hydrochloride capsule formu-
lation used in GAIT, suggested that the peak levels might be
much lower. The aim of the present study was therefore to
investigate in a direct comparative study, the relative bioavail-
ability of glucosamine following repeated oral administration of
the two glucosamine salt formulations and dose regimens, or
of the glucosamine hydrochloride/chondroitin sulfate combina-
tion, to assess if differences in exposure to the active ingredient
and especially in peak plasma levels, might provide a possible
explanation for the contrasting clinical results.
Methods: Twelve healthy volunteers (5 males and 7 females)
received three consecutive once-daily oral administrations of
crystalline glucosamine sulfate soluble powder at the dose of
1500 mg, or glucosamine hydrochloride capsules at the dose
of 500 mg t.i.d. for thee consecutive days either alone or in
combination with chondroitin sulfate 400 mg t.i.d. in an open,
randomised, cross-over fashion. Glucosamine was determined
at steady state in plasma collected up to 48 h after the last dose
by a validated LC-MS/MS method.
Results: Glucosamine was bioavailable after administration of
the three products. After crystalline glucosamine sulfate 1500 mg
once-daily, peak concentrations (Css,max) and extent of exposure
(AUCss) averaged 9.1±6.3 µM and 76.5±23.0 µM.h, respec-
tively. Signiﬁcantly (p≤0.005) lower plasma concentrations were
determined after the administration of 500 mg glucosamine hy-
drochloride alone (Css,max and AUCss averaged 4.5±1.8 µM and
21.4±7.6 µM.h, respectively) or in combination with 400 mg of
chondroitin sulfate (Css,max and AUCss averaged 3.3±1.0 µM and
13.8±5.4 µM.h, respectively).
Conclusions: Administration of glucosamine hydrochloride at
the dose of 500 mg t.i.d might produce a similar extent of
systemic exposure to glucosamine throughout the day, but at
signiﬁcantly lower (less than a half) peak plasma concentra-
tions compared to 1500 mg of crystalline glucosamine sulfate
